Novasorb
Trademark details
Novasorb® is a registered trademark used for Ocular Pharmaceuticals and owned by Novagali Pharma Sa. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Ocular Pharmaceuticals Pharmaceutical Preparations For Ocular or Intraocular Surgery Pharmaceutical Preparations, Namely, Preparations For Use In the Treatment of Conjunctivitis, For Use In the Treatment of Infectious Diseases, For Use In the Treatment of Gastro-Intestinal Disorders, For Use In the Treatment of Pulmonary Hypertension, For Use In Treating Diabetes, For Use In Treating Skin Disorders Sanitary Preparations For Medical Purposes Eye-Washes Eye Drops Artificial Tears and Emulsions For Treatment of Dry Eyes Irrigating Solutions and Viscoelastic Agents For Eye Use Serums For the Treatment of Skin Disorders, Medicated Skin Serums, Medicated Anti-Aging Facial Serums Ophthalmic Emulsions, Namely, Contact Lens Solutions, Eye Drops, Eye Lubricants Chemical-Pharmaceutical Preparations, Namely, Preparations For Use In the Treatment of Cancer and Malignant Disease, Chemotherapeutic Drugs, For Use In the Treatment of Rheumatism Lotions For Pharmaceutical Purposes, Namely, Medicated Skin Care Lotions For the Treatment of Rashes, Medicated Lotions For the Treatment of Poison Ivy Tissues Impregnated With Pharmaceutical Lotions, Namely, Medicated Pre-Moistened Tissues Medicines For Human Medical Purposes, Namely, Medicines For Treatment of Eye Diseases, Macular Degeneration, Diabetic Retinopathy and Uvietis, Antiallergic Medicines, Medicines For the Treatment of Gastrointestinal Diseases, Antipyretics, Analgesics, Drugs For Osteoporosis, Antibiotic Drugs, Antifungal Drugs, Drugs For Parasitism, Antimicrobial Drugs, Medicines For the Treatment of Cancers, Cardiovascular Diseases, Diseases of Respiratory System, Diseases of Digestive System, Diseases of Nervous System, Diseases of Urinary System, Diseases of Blood and Circulatory System, Diseases of Endocrine System, Diseases of Immune System, For Use In the Treatment of Acute Cerebral Infarctions Therapeutic Preparations, Namely Ophthalmic Preparations, Ophthalmologic Preparations, Glaucoma Agents and Preparations For Use In the Treatment of Cancer and Malignant Diseases Dressings For Use In the Treatment of Wounds and Burns and Surgical Dressings Herbal Infusions For Medical Purposes, Namely, Herbal Medicinal Beverages Bath Salts For Medical Purposes Plasters, Namely, Corn Plasters, Medical Plasters Oral and Dental Care Products For Medical Use, Namely, Dentifrices, Dental Gels, Oral Rinses, Fluoride Treatments, Mouth Sprays and Desensitizers |
| Serial Number: | 79012596 |
| Registration Number: | 3202278 |
| Filing Date: | Mar 11, 2005 |
|
Last Applicant(s)/ Owner(s) of Record | Novagali Pharma Sa1, Rue Pierre Fontaine - |
| Related Products: | Pharmaceuticals |
Web Sites
powered by 
Total : 33,300 View more »
Novagali Pharma - Novasorb
cationic emulsion topical surface and anterior segment ... Novasorb ® is a cationic emulsion developed to address the main challenges of topical ocular drug ...
New Dry Eye Therapy Available Soon - Welcome to OCuSOFT, Inc.
Dry Eye Therapy Utilizing Cationic Novasorb Technology. Available Soon From OCuSOFT . FOR IMMEDIATE RELEASE. Richmond, TX (June 14, 2011) – OCuSOFT, Inc., an ...
Dry Eye Therapy Utilizing Cationic Novasorb® Technology Available ...
Dry Eye Therapy Utilizing Cationic Novasorb® Technology Available Soon From OCuSOFT®.
Successfully Improving Ocular Drug Delivery Using the Cationic ...
In the last decade, Novagali Pharma has successfully developed and marketed Novasorb, an advanced pharmaceutical technology for the treatment of ophthalmic diseases.
News and Blogs
Total : 2 View more »
DRY EYE: Award Winning Technology Solves Dilemma for Patients
...resulting from Novagali’s patented Novasorb® technology whose efficiency...corneal epithelium of the ocular surface, Novasorb’s technological platform enables...Grand Prix de l’Innovation for Novasorb®. Novagali Pharma carried out a successful...
Drug Pipeline Progress May 4-15 | News | Drug Discovery and Development Magazine
...proprietary BAK-free formulation of latanoprost which furthermore benefits from the ocular surface protection properties of Novasorb. HPN-100 Company: Hyperion Therapeutics HPN-100 Has Received Orphan Product Designation From The FDA, May 5...
Explore Related Topics:
Related Products:
